LifeMD (LFMD) Expected to Announce Quarterly Earnings on Monday

LifeMD (NASDAQ:LFMD - Get Free Report) will likely be releasing its earnings data after the market closes on Monday, March 10th. Analysts expect LifeMD to post earnings of ($0.04) per share and revenue of $57.43 million for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.

LifeMD Price Performance

Shares of LifeMD stock traded down $0.16 on Thursday, hitting $4.83. 2,133,294 shares of the company's stock traded hands, compared to its average volume of 764,474. The firm's 50-day moving average price is $5.67 and its two-hundred day moving average price is $5.38. The stock has a market capitalization of $209.20 million, a PE ratio of -7.55 and a beta of 1.50. LifeMD has a one year low of $3.99 and a one year high of $12.88.

Insider Transactions at LifeMD

In related news, CEO Justin Schreiber sold 50,000 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $7.55, for a total value of $377,500.00. Following the completion of the transaction, the chief executive officer now directly owns 2,653,715 shares in the company, valued at approximately $20,035,548.25. The trade was a 1.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 15.97% of the stock is currently owned by insiders.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on LFMD shares. Lake Street Capital started coverage on LifeMD in a report on Tuesday, December 10th. They issued a "buy" rating and a $12.00 price objective for the company. KeyCorp lowered their price target on LifeMD from $10.00 to $7.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. HC Wainwright reissued a "buy" rating and set a $12.00 price objective on shares of LifeMD in a research note on Monday, November 11th. Finally, Mizuho started coverage on shares of LifeMD in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $7.00 target price for the company. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, LifeMD has a consensus rating of "Moderate Buy" and an average target price of $11.14.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.